Arzu Oğuz

454 total citations
36 papers, 310 citations indexed

About

Arzu Oğuz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Arzu Oğuz has authored 36 papers receiving a total of 310 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Arzu Oğuz's work include Peptidase Inhibition and Analysis (4 papers), Lung Cancer Diagnosis and Treatment (4 papers) and HER2/EGFR in Cancer Research (4 papers). Arzu Oğuz is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Lung Cancer Diagnosis and Treatment (4 papers) and HER2/EGFR in Cancer Research (4 papers). Arzu Oğuz collaborates with scholars based in Türkiye, Italy and India. Arzu Oğuz's co-authors include Dilek Ünal, Arzu Taşdemi̇r, Celalettin Eroğlu, Sema Sezgin Göksu, Yasemin Benderli Cihan, Hasan Mutlu, Serap Tomruk Sütbeyaz, Özden Altundağ, Mehmet Kanbay and Hati̇ce Karaman and has published in prestigious journals such as Journal of Clinical Oncology, Archives of Physical Medicine and Rehabilitation and Journal of Clinical Psychopharmacology.

In The Last Decade

Arzu Oğuz

30 papers receiving 302 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arzu Oğuz Türkiye 9 205 63 60 53 39 36 310
Ömer Fatih Ölmez Türkiye 9 161 0.8× 48 0.8× 56 0.9× 48 0.9× 37 0.9× 52 284
Benjamin M. Parsons United States 12 204 1.0× 90 1.4× 90 1.5× 38 0.7× 59 1.5× 36 440
Katrin Hefler‐Frischmuth Austria 11 204 1.0× 59 0.9× 118 2.0× 71 1.3× 31 0.8× 17 479
Greg Hapgood Australia 9 123 0.6× 64 1.0× 36 0.6× 66 1.2× 29 0.7× 28 390
Nagla Abdel Karim United States 9 133 0.6× 43 0.7× 116 1.9× 39 0.7× 53 1.4× 33 275
Won Jin Chang South Korea 12 177 0.9× 91 1.4× 110 1.8× 30 0.6× 79 2.0× 27 353
Sugganth Daniel United States 7 196 1.0× 70 1.1× 96 1.6× 46 0.9× 62 1.6× 26 313
F. Majois Belgium 9 224 1.1× 59 0.9× 69 1.1× 29 0.5× 56 1.4× 28 350
Yasemi̇n Kemal Türkiye 9 264 1.3× 75 1.2× 81 1.4× 56 1.1× 28 0.7× 27 334
Ping‐Tsung Chen Taiwan 14 201 1.0× 59 0.9× 126 2.1× 120 2.3× 69 1.8× 35 436

Countries citing papers authored by Arzu Oğuz

Since Specialization
Citations

This map shows the geographic impact of Arzu Oğuz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arzu Oğuz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arzu Oğuz more than expected).

Fields of papers citing papers by Arzu Oğuz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arzu Oğuz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arzu Oğuz. The network helps show where Arzu Oğuz may publish in the future.

Co-authorship network of co-authors of Arzu Oğuz

This figure shows the co-authorship network connecting the top 25 collaborators of Arzu Oğuz. A scholar is included among the top collaborators of Arzu Oğuz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arzu Oğuz. Arzu Oğuz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Altundağ, Özden, et al.. (2025). Artificial intelligence for immunotherapy response assessment in lung cancer using PET/CT reports. Japanese Journal of Radiology. 43(12). 2042–2050.
2.
Oğuz, Arzu, et al.. (2024). Cisplatin versus carboplatin in small cell lung cancer (SCLC): Single-center experience.. Journal of Clinical Oncology. 42(16_suppl). e20116–e20116.
3.
Oğuz, Arzu, et al.. (2024). A Case Report and Mini Review on Clozapine Treatment During Chemotherapy. Journal of Clinical Psychopharmacology. 44(5). 522–524.
4.
Soy, Ebru H. Ayvazoğlu, et al.. (2020). Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant. Experimental and Clinical Transplantation. 18(2). 201–205. 3 indexed citations
5.
Oğuz, Arzu, et al.. (2020). The impact of lymph node ratio on overall survival in patients with colorectal cancer. Journal of Cancer Research and Therapeutics. 17(4). 1069–1074. 8 indexed citations
6.
Çiftci, Orçun, Kerem Can Yılmaz, Emir Karaçağlar, et al.. (2019). The Role of Selvester Score on 12-Lead ECG in Determination of Left Ventricular Systolic Dysfunction Among Patients Receiving Trastuzumab Therapy. European Journal of Therapeutics. 25(1). 69–75. 3 indexed citations
7.
Oğuz, Arzu, et al.. (2017). Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes.. PubMed. 21(5). 1076–1081. 7 indexed citations
8.
Arık, Ferhat, et al.. (2017). There is a relation between blood subgroups and insulin resistance. 2 indexed citations
9.
Sütbeyaz, Serap Tomruk, et al.. (2016). Extracorporeal Shock Wave Therapy for Breast Cancer–Related Lymphedema: A Pilot Study. Archives of Physical Medicine and Rehabilitation. 97(9). 1520–1525. 30 indexed citations
10.
Ünal, Dilek, Celalettin Eroğlu, Arzu Taşdemi̇r, et al.. (2015). Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?. Cancer Research and Treatment. 48(1). 98–105. 11 indexed citations
11.
Ünal, Dilek, Arzu Oğuz, Sema Sezgin Göksu, et al.. (2014). EFFECT OF PROGNOSTIC FACTORS ON SURVIVAL IN ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER. The Turkish Journal of Geriatrics. 17(2). 113–118.
12.
Oğuz, Arzu, et al.. (2014). Morphine: Patient Knowledge and Attitudes in the Central Anatolia Part of Turkey. Asian Pacific Journal of Cancer Prevention. 15(12). 4983–4988. 10 indexed citations
13.
Ünal, Dilek, et al.. (2014). Lack of any Association between Season of Diagnosis and Survival of Gastric Cancer Cases in Kayseri, Turkey. Asian Pacific Journal of Cancer Prevention. 15(4). 1763–1766. 5 indexed citations
14.
Oğuz, Arzu, et al.. (2014). Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy. Asian Pacific Journal of Cancer Prevention. 15(3). 1411–1414. 6 indexed citations
15.
Dızdar, Ömer, Arzu Oğuz, Selim Yalçın, et al.. (2014). Good Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Alone. Asian Pacific Journal of Cancer Prevention. 15(9). 3891–3893. 8 indexed citations
16.
Oğuz, Arzu, et al.. (2013). Malignant peritoneal mesothelioma: Two cases and literature review. International Journal of Medicine and Medical Sciences. 5(3). 95–96. 1 indexed citations
17.
Ünal, Dilek, et al.. (2013). Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Rates in Patients with Non-Small Cell Lung Cancer Associated with Treatment Response and Prognosis?. Asian Pacific Journal of Cancer Prevention. 14(9). 5237–5242. 125 indexed citations
18.
Oğuz, Arzu, Dilek Ünal, Arzu Taşdemi̇r, et al.. (2013). Lack of any Association between Blood Groups and Lung Cancer, Independent of Histology. Asian Pacific Journal of Cancer Prevention. 14(1). 453–456. 28 indexed citations
19.
Oğuz, Arzu, et al.. (2013). Season of Diagnosis and Survival of Advanced Lung Cancer Cases - Any Correlation?. Asian Pacific Journal of Cancer Prevention. 14(7). 4325–4328. 5 indexed citations
20.
Dirikoç, Ahmet, Arzu Oğuz, Didem Özdemir, et al.. (2012). Prevalence of thyroid diseases in patients with colon cancer and benign colon polyps. 15th International & 14th European Congress of Endocrinology. 29. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ömer Fatih Ölmez Breakdown of academic impact, for papers by Benjamin M. Parsons Breakdown of academic impact, for papers by Katrin Hefler‐Frischmuth Breakdown of academic impact, for papers by Greg Hapgood Breakdown of academic impact, for papers by Nagla Abdel Karim Breakdown of academic impact, for papers by Won Jin Chang Breakdown of academic impact, for papers by Sugganth Daniel Breakdown of academic impact, for papers by F. Majois Breakdown of academic impact, for papers by Yasemi̇n Kemal Breakdown of academic impact, for papers by Ping‐Tsung Chen
Rankless by CCL
2026